COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Arrive AI Announces Third Quarter 2025 Results, Continued Momentum on Strategic and Operating Milestones
Arrive AI (NASDAQ: ARAI) reports Q3 2025 highlights, financial results, strategic partnerships, and product updates. CEO Dan O'Toole emphasizes growth plans and innovative technologies -
-
COMMUNIQUÉ DE PRESSE
DeFi Technologies Inc. Announces Q3 2025 Financial Results: Revenues of $22.5 million, Operating Income of $9 million, and CEO Transition
DeFi Technologies Inc. reports Q3 2025 financial results, including $22.5 million revenues and $9 million operating income. CEO transition announced -
COMMUNIQUÉ DE PRESSE
SdK calls on bondholders of paragon GmbH & Co. KGaA to pool their interests
SdK calls on bondholders of paragon GmbH & Co. KGaA to pool their interests in voting for bond extension and interest payment deferral. Investor association SdK offers support and information to bondholders -
COMMUNIQUÉ DE PRESSE
Original-Research: Diversified Energy PLC (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Diversified Energy PLC (ISIN: GB00BYX7JT74) with a BUY rating and a target price of GBp2600, reflecting strong Q3/25 performance and raised EBITDA guidance for 2025 -
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
Le Teizeild de Sanofi reçoit l'approbation du CHMP pour retarder l'apparition du stade 3 du diabète de type 1 chez les patients de stade 2. Première thérapie de fond potentielle dans l'UE -
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi's Teizeild recommended for EU approval for stage 2 type 1 diabetes based on positive CHMP opinion. TN-10 study shows Teizeild delays the onset of stage 3 T1D
